Comparison of In vivo toxicity and anti-glatiramer acetate IgG antibody titers in rats Treated with glatiramer acetate (Copaxone) and follow-on glatiramer acetate (FOGA) products

被引：0
|
作者：
Konya, A. [1 ]
Timan, B. [2 ]
Ashkenazi, N. [2 ]
Bursztyn, D. [2 ]
Gyure, L. [1 ]
Vardi, M. [2 ]
Alexander, J. [3 ]
Loupe, P. [4 ]
Nock, S. [5 ]
机构：
[1] Teva Pharmaceut Ind Ltd, Debrecen, Hungary
[2] Teva Pharmaceut Ind Ltd, Netanya, Israel
[3] Teva Pharmaceut Ind Ltd, Denver, CO USA
[4] Teva Pharmaceut Ind Ltd, Overland Pk, KS USA
[5] Teva Pharmaceut Ind Ltd, Redwood City, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P678
引用
收藏
页码：337 / 337
页数：1
相关论文
共 43 条
  • [11] Integrated Transcriptomic and Physicochemical Characterization of Glatiramer Acetate Products (Copaxone and Glatopa) Available in the United States
    Komlosh, Arthur
    Laifenfeld, Daphna
    Kolitz, Sarah
    Fowler, Kevin
    Hasson, Tal
    Konya, Attila
    Bakshi, Shlomo
    Zeskind, Benjamin
    Zhang, Jenny
    Wells-Knecht, Kevin
    Molotsky, Tatiana
    Krispin, Revital
    Papir, Galia
    Pinkert, Dalia
    Cooperman, Helena
    Weinstein, Vera
    Sahly, Yousif
    Loupe, Pippa
    Melamed-Gal, Sigal
    Grossman, Iris
    Hayden, Michael
    NEUROLOGY, 2018, 90
  • [12] Surface charge distribution, an attribute linked with immunogenicity of nanoparticles, is different for follow-on glatiramer acetate products approved in EU, Russia, Latin America and USA compared with Copaxone
    Komlosh, A.
    Krispin, R.
    Papir, G.
    Molotsky, T.
    Sahly, Y.
    Weinstein, V.
    Gilbert, A.
    Melamed-Gal, S.
    Loupe, P.
    Grossman, I.
    Laufer, R.
    Hayden, M. R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 869 - 869
  • [13] Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β
    Buron, Mathias Due
    Magyari, Melinda
    Chalmer, Thor Ameri
    Sorensen, Per Soelberg
    Sellebjerg, Finn
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [14] Biological and Immunological Equivalence of Two FDA-Approved Glatiramer Acetate Products (Glatopa™ and Daily COPAXONE® 20 mg)
    D'Alessandro, Josephine
    Garofalo, Kevin
    Zhao, Ganlin
    Honan, Christopher
    Duffner, Jay
    Pradines, Joel
    Capila, Ishan
    Fier, Ian
    Kaundinya, Ganesh
    Kantor, Daniel
    Ganguly, Tanmoy
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 23 - 23
  • [15] Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
    Johnson, KP
    Brooks, BR
    Ford, CC
    Goodman, AD
    Lisak, RP
    Myers, LW
    Pruitt, AA
    Rizzo, MA
    Rose, JW
    Weiner, LP
    Wolinsky, JS
    MULTIPLE SCLEROSIS, 2003, 9 (06): : 585 - 591
  • [16] COPAXONE® active registry - documentation of efficacy, tolerability and quality of life in outpatients with relapsing remitting multiple sclerosis (RRMS) treated with glatiramer acetate
    Ziemssen, T.
    Faude, U.
    Fendji, D.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 639 - 640
  • [17] Twenty-four-month comparison of immunomodulatory treatments -: a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)
    Haas, J
    Firzlaff, M
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (06) : 425 - 431
  • [18] COPAXONE® Active Registry-Documentation of efficacy, tolerability and quality of life in outpatients with relapsing remitting multiple sclerosis (RRMS) treated with glatiramer acetate
    Faude, U.
    Ziemssen, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 418 - 418
  • [19] Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients:: an open-label 2-year follow-up
    Flechter, S
    Vardi, J
    Pollak, L
    Rabey, JM
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 197 (1-2) : 51 - 55
  • [20] Ex-vivo cellular IL-4/IFN-gamma ratio correlates with clinical response to glatiramer acetate (copaxone) in multiple sclerosis
    Valenzuela, RM
    Costello, K
    Johnson, KP
    Dhib-Jalbut, S
    NEUROLOGY, 2005, 64 (06) : A418 - A418
12345